Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Strand Therapeutics
Pharma
Summit, UCB-Candid, J&J—Fierce Pharma Asia
Summit's PD-1xVEGF trial missed an interim analysis. UCB will buy Candid for $2 billion. J&J cut two CAR-T programs from its AbelZeta deal.
Angus Liu
May 8, 2026 8:30am
Fierce Biotech
Strand Tx CEO Jake Becraft weighs in on FDA's IND reform, China
May 4, 2026 12:00pm
'The Top Line': The Fierce 15, Fierce Biotech Summit highlights
Sep 30, 2022 6:00am
